Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Eosinophilic Granulomatosis With Polyangiitis: full-pipeline trial registry
3 of 4 indexed Eosinophilic Granulomatosis With Polyangiitis trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Eosinophilic Granulomatosis With Polyangiitis: 4 US clinical trials tracked, 3 recruiting.
Eosinophilic Granulomatosis With Polyangiitis is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of Pennsylvania, running 2 of these trials.
Enrollment posture brief
Registry condition eosinophilic-granulomatosis-with-polyangiitis
OPEN 3 | RECR 75% | LATE 1 | EARLY 1 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Eosinophilic Granulomatosis With Polyangiitis lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Eosinophilic Granulomatosis With Polyangiitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Eosinophilic Granulomatosis With Polyangiitis is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
VCRC Tissue Repository
University of Pennsylvania
NCT02967068
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
University of Pennsylvania
NCT00315380
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NS Pharma
NCT06046222
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
GlaxoSmithKline
NCT05263934
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Eosinophilic Granulomatosis With Polyangiitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Eosinophilic Granulomatosis With Polyangiitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Eosinophilic Granulomatosis With Polyangiitis page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Eosinophilic Granulomatosis With Polyangiitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Pennsylvania sponsors the most Eosinophilic Granulomatosis With Polyangiitis trials on record, review their full trial history before evaluating a specific study. See University of Pennsylvania's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Eosinophilic Granulomatosis With Polyangiitis condition card totals 4 registered trials; most-linked intervention Placebo matching depemokimab; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.